학술논문
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
Document Type
Article
Author
Reilmann, R.; Schubert, R.; Anderson, K.E.; Feigin, A.; Tabrizi, S.J.; Leavitt, B.R.; Hayden, M.; Stout, J.C.; Piccini, P.; Loupe, P.; Rynkowski, G.; Volkinshtein, R.; Li, T.; Gordon, M.F.; Wickenberg, A.; Borowsky, B.; Savola, J.-M.; Guttman, M.; Raymond, L.; Mendis, T.; Suchowersky, O.; Corey-Bloom, J.; Geschwind, M.D.; Marshall, F.J.; Marder, K.S.; Nance, M.; Racette, B.; Bang, J.; Segro, V.; McDonell, K.; Kamholz, J.; LeDoux, M.S.; Sanchez-Ramos, J.; DeMichele, G.; Mariotti, C.; Squitieri, F.; Soliveri, P.; Cortelli, P.; Muñoz García, J.E.; Kulisevsky Bojarski, J.; López-Sendón Moreno, J.L.; Berganzo Corrales, K.; Cubo, E.; García Moreno, J.M.; Orth, M.; Priller, J.; Saft, C.; Weindl, A.; Winkler, J.; Craufurd, D.; Miedzybrodzka, Z.; Rickards, H.; Davies, R.R.; Lahiri, N.; Ruddy, D.; Komati, S.K.; Quarrell, O.W.J.; Correira Guedes, L.; Roos, R.A.C.; Zalyalova, Z.; Illarioshkin, S.; Gustov, A.; Klempir, J.
Source
In: The Lancet Neurology . (The Lancet Neurology, March 2024, 23(3):243-255)
Subject
Language
English
ISSN
14744465
14744422
14744422